Persistence of Cryptococcus neoformans in seminal fluid and urine under itraconazole treatment. The urogenital tract (prostate) as a niche for Cryptococcus neoformans.
The open questions of the persistence of Cryptococcus neoformans in the urogenital tract under antimycotic treatment can be examined under optimal mycological-diagnostic conditions only. The example of a case of cryptococcosis in an AIDS patient diagnosed and treated with itraconazole in the early secondary stage of cryptococcosis is used to discuss the problems of the persistence of Cr. neoformans involvement in the urogenital tract (prostate). Data from a ten-week follow-up study are presented and discussed. The observations made have shown that itraconazole is effective in all regions of the body, with the exception of the urogenital tract. In addition to clinical examinations, cases treated with itraconazole should be finally subjected to cultural examination of prostatic secretion and/or seminal fluid, to exclude the possible presence of a symptom-free involvement of the prostate by Cr. neoformans.
Staib
F
F
Mycology Unit, Robert Koch Institute, Berlin, Germany, FR.
Seibold
M
M
L'age
M
M
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D003453:Cryptococcosis / Q000188:drug therapy* / Q000382:microbiology; D003455:Cryptococcus neoformans / Q000254:growth & development*; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D011467:Prostate / Q000382:microbiology*; D012661:Semen / Q000382:microbiology; D014556:Urine / Q000382:microbiology
D000935:Antifungal Agents; D017964:Itraconazole; D007654:Ketoconazole